-The Times of India NEW DELHI: Leading US health groups including AVAC, Oxfam America, amfAR, Health Global Access Project (GAP), TAG (Treatment Action Group)and others have written to Barack Obama urging him to support India in providing "high-quality, low-cost generic medicines essential for health care around the world". This comes in the wake of the two nations agreeing to enhance engagement on IPR at the latest bilateral talks. Sunday's joint statement after...

-The Telegraph New Delhi: Health and patients' rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India's patent laws that allow drug companies to sell inexpensive generic medicine. Health activists representing patients' rights said they were concerned that bilateral talks on intellectual property rights, to feature during US President Barack Obama's visit to India beginning this weekend, may be rigged against...

-The Telegraph New Delhi: The Narendra Modi government may introduce a health cess to fund free health care services and launch seven preventive campaigns to curb illnesses under a draft health policy unveiled today. Some analysts, however, said the draft of the National Health Policy 2015 lacked emphasis on regulating India's private health industry, necessary to curb the high cost of health care. The draft says the government has the "political will" to...

-The Hindu New Delhi: While observing that the Court could not encroach into policy matters of the government, the Delhi High Court has dismissed a public interest writ petition seeking directions to the Centre to make available generic medicines and medical treatment to the public at large at a reasonable cost. A Division Bench comprising Chief Justice G. Rohini and Justice R.S. Endlaw had earlier this week said that the Centre and...

-The Hindu In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer's appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals. Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the...